Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humoral Immunity After Soberana Plus Booster
NCT05689177Unknown
- Sponsor
- Gomel State Medical University
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of FINLAY-FR-1A in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Gomel State Medical University. Primary endpoint: SARS-CoV-2 Class G Immunoglobulins Level at 180 days. Status: unknown.
02
Drugs
FINLAY-FR-1A
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05689177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689177.